Search

everythinglearnresearchcommunity

for

Search:↓

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

The combination treatment showed a higher response rate but no significant survival benefits.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

The combination of encorafenib and binimetinib caused few skin issues.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Promising cancer treatments were found, but the manufacturer closed.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Ocrelizumab may cause pancreatitis in some patients.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Suppressing ODC activity reduces tumor growth in hair follicles.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Anti-CD19 therapy may help treat SLE and NMOSD.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.